Healthcare Finance

The FDA is preparing to restrict compounded semaglutide and tirzepatide prescriptions as brand-name supply stabilizes, directly threatening telehealth platforms like TomorrowsRx that built businesses on compound weight-loss medications. The regulatory shift would eliminate the legal pathway these companies use to offer lower-cost alternatives to Ozempic and Mounjaro.

The biotechnology sector is approaching a pivotal transition as gene therapy, mRNA, and cell therapy programs simultaneously near commercialization. With major players including Moderna, Regeneron, CRISPR Therapeutics, and REGENXBIO targeting BLA submissions and product launches through 2026–2027, the funding and financing landscape for biotech is shifting from risk capital to revenue-generation models. Investors are watching closely as pipeline assets convert to commercial platforms.